Skip to main content

Table 2 Effects of DPP-4 inhibitors and SGLT2 inhibitor on blood pressure, body weight, and glucose and lipid levels

From: A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes

 

Total

(n = 184)

DPP-4 inhibitors

Linagliptin (n = 55)

Gemigliptin (n = 69)

SGLT2 inhibitor

(n = 60)

p-value

 

Baseline

24 weeks

Baseline

24 weeks

Baseline

24 weeks

 

Total cholesterol (mg/dl)

175.4 ± 39.6

167.0 ± 35.8*

174.9 ± 40.5

165.9 ± 34.4**

176.6 ± 38.2

169.2 ± 38.7

 

Change from baseline

−8.5 (−13.7, −3.2)

−9.0 (−15.8, −2.1)

−7.4 (−15.4, 0.6)

0.836

Total triglycerides (mg/dl)

165.7 ± 96.2

150.5 ± 88.0*

172.9 ± 105.3

159.9 ± 94.5

150.3 ± 71.2

130.6 ± 68.6

 

Change from baseline

−15.2 (−28.7, −1.3)

−13.0 (−30.8, 4.7)

−19.7 (−39.7, 0.3)

0.867

LDL cholesterol (mg/dl)

98.3 ± 32.7

93.0 ± 29.8*

99.0 ± 33.9

90.6 ± 28.6**

96.7 ± 30.3

97.9 ± 31.7

 

Change from baseline

−5.3 (−9.6, −1.0)

−8.4 (−14.0, −2.8)

1.3 (−5.1, 7.6)

0.046***

HDL cholesterol (mg/dl)

43.5 ± 10.4

45.5 ± 11.0*

42.7 ± 10.2

42.2 ± 10.0

45.3 ± 10.6

50.3 ± 11.3**

 

Change from baseline

2.0 (0.8, 3.2)

0.5 (−0.9, 2.0)

5.1 (3.0, 7.1)

0.001***

Apolipoprotein A (g/l)

121.6 ± 19.4

131.4 ± 26.8*

115.6 ± 18.5

120.5 ± 22.0

126.1 ± 17.9

139.8 ± 28.8**

 

Change from baseline

9.8 (3.7, 16.0)

6.5 (−3.7, 12.6)

13.7 (4.8, 22.7)

0.726

Apolipoprotein B (g/l)

91.2 ± 21.5

86.4 ± 22.0

88.6 ± 21.8

81.3 ± 14.4

95.8 ± 21.3

90.3 ± 26.6

 

Change from baseline

−4.8 (−11.3, 1.7)

−0.6 (−15.9, 8.3)

−5.5 (−13.5, 2.4)

0.660

Lipoprotein (a) (mg/dl)

17.7 ± 18.4

17.2 ± 19.8

17.2 ± 23.6

20.0 ± 25.4

15.6 ± 16.2

15.8 ± 19.3

 

Change from baseline

−0.6 (−2.6, 1.5)

−0.9 (−3.4, 1.6)

0.2 (−4.2, 4.6)

0.991

Fasting plasma glucose (mg/dl)

172.8 ± 58.1

151.3 ± 44.9*

171.8 ± 58.8

150.8 ± 43.1**

174.8 ± 57.1

150.1 ± 48.7**

 

Change from baseline

−21.5 (−31.2, −11.9)

−16.9 (−30.5, −9.5)

−24.8 (−45.4, −4.1)

0.462

HbA1c (%(mmol/mol))

8.5 ± 1.3

(69.4 ± 13.7)

7.8 ± 1.3*

(61.9 ± 13.8)

8.6 ± 1.3

(70.5 ± 14.3)

7.9 ± 1.3**

(62.6 ± 14.6)

8.3 ± 1.1

(67.2 ± 12.4)

7.7 ± 1.1**

(60.3 ± 12.1)

 

Change from baseline

−0.7 (−0.9, −0.5)

−7.8 (−9.9, −5.7)

−0.8 (−1.0, −0.5)

−8.2 (−10.9, −5.5)

−0.6 (−0.9, −0.3)

−13.2 (−10.3, −3.5)

0.593

Systolic blood pressure (mmHg)

125.3 ± 12.9

124.5 ± 11.8

123.3 ± 14.1

124.4 ± 13.3

128.8 ± 10.1

124.6 ± 9.0**

 

Change from baseline

−0.9 (−4.0, 2.3)

1.1 (−3.4, 5.7)

−4.2 (−7.6, −0.7)

0.112

Diastolic blood pressure (mmHg)

76.2 ± 12.2

74.5 ± 9.1

75.3 ± 12.3

74.7 ± 9.4

77.7 ± 12.1

74.3 ± 8.7**

 

Change from baseline

−1.7 (−4.2, 0.8)

−0.6 (−3.9, 2.6)

−3.4 (−7.5, 0.7)

0.304

Body weight (kg)

69.6 ± 11.3

68.7 ± 11.1*

68.8 ± 10.9

68.3 ± 10.8

71.1 ± 11.9

69.5 ± 11.6**

 

Change from baseline

−0.9 (−1.4, −0.4)

−0.5 (−0.7, −0.3)

−1.5 (−2.1, −0.9)

<0.001***

  1. Data are means ± SD, or 95% CI. p < 0.05 was considered significant. Changes from baseline and percent change from baseline are adjusted for age, sex, diabetes duration, BMI, and glucose control status (HbA1c difference). DPP-4 dipeptidyl peptidase 4, SGLT2 sodium glucose cotransporter 2, LDL low-density lipoprotein, HDL high-density lipoprotein, Hemoglobin A1c HbA1c
  2. * p < 0.05 (comparison between before treatment and after treatment in all subjects)
  3. ** p < 0.05 (comparison between before treatment and after treatment in each group)
  4. *** p < 0.05 (comparison between DPP-4 inhibitor group and SGLT2 inhibitor group)
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X